Biological Depiction of Lipodystrophy and Its Associated Challenges Among HIV AIDS Patients: Literature Review

References

• Santini DAVF, Santini F. Diagnosis and treatment of lipodystrophy: a step - by - step approach. J Endocrinol Invest. 2019;42(1):61–73. doi:10.1007/s40618-018-0887-z
   PubMed Web of Science ®Google Scholar
• Awino McLigeyo A, Lule G, Otieno FCF, Joshua Kyateesa Kayima EO. Human immunodeficiency virus (HIV) associated lipodystrophy: the prevalence, severity and phenotypes in patients on highly active anti-retroviral therapy (HAART) in Kenya. J AIDS HIV Res. 2013;5(4):107–114.
   Google Scholar
• López-dupla M, Maymó-masip E, Martínez E, Domingo P. HIV-1 / HAART-Related Lipodystrophy Syndrome (HALS) is associated with decreased circulating sTWEAK levels. PLoS One. 2015;10(12):1–13. doi:10.1371/journal.pone.0144789
   Web of Science ®Google Scholar
• Gomes L, Lana C, Rezende D, Junqueira G, Perini E, Pádua De CM. Lipodystrophy among patients with HIV infection on antiretroviral therapy: a systematic review protocol. BMJ Open. 2014;4:10–13.
   Web of Science ®Google Scholar
• Barton N, Moore R, Prasad K, Evans G. Excisional lipectomy versus liposuction in HIV-associated lipodystrophy. Arch Plast Surg. 2021;48(6):685–690.
   PubMedGoogle Scholar
• Martinez E, Mocroft A, García-viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(February 24):592–598. doi:10.1016/S0140-6736(00)04056-3
   PubMedGoogle Scholar
• Siqueira LR, Holanda G, Teresinha M, et al. Effect of lipodystrophy on self-esteem and adherence to antiretroviral therapy in people living with HIV. AIDS Care. 2021;1(1):1–10. doi:10.1080/09540121.2021.1936442
   Google Scholar
• Grenha I, Oliveira J, Lau E, et al. HIV-Infected Patients With and Without Lipodystrophy Under Combined Antiretroviral Therapy: evaluation of Body Composition. J Clin Densitom. 2018;21(1):75–82. doi:10.1016/j.jocd.2016.07.010
   PubMed Web of Science ®Google Scholar
• Dragovi G, Danilovi D, Dimi A, Jevtovi D. Lipodystrophy induced by combination antiretroviral therapy in HIV / AIDS patients: a Belgrade cohort study. Vojn Pregl. 2014;71(8):746–750. doi:10.2298/VSP121016022D
   PubMed Web of Science ®Google Scholar
• Bouatou Y, Gayet Ageron A, Bernasconi E, et al. Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: the LIPOKID Study. Kidney Int Reports. 2018;3(5):1089–1099. doi:10.1016/j.ekir.2018.04.014
   PubMed Web of Science ®Google Scholar
• Finkelstein JL, Gala P, Rochford R, Glesby MJ, Mehta S. HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc. 2015;18(1):1–13. doi:10.7448/IAS.18.1.19033
   Google Scholar
• Leow MK, Addy CL and Mantzoros CS. (2003). Human immunodeficiency Virus/Highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocr Metab, 88(5), 1961–1976. 10.1210/jc.2002-021704
   PubMed Web of Science ®Google Scholar
• Sacilotto LB, Papini SJ, Mendes AL, et al. Relationship Between Lipodystrophy, Body Composition, Metabolic Profile, and Serum Levels of Adipocytokines. Front Nutr. 2021;8(December). doi:10.3389/fnut.2021.750721
   PubMedGoogle Scholar
• Marcelle D, Sprinz E. HIV-associated lipodystrophy: a review from a Brazilian perspective. Ther Clin Risk Manag. 2014;10:559–566. doi:10.2147/TCRM.S35075
   PubMed Web of Science ®Google Scholar
• Bhutia E, Hemal A, Yadav TP, Ramesh KL. Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India. Afr Health Sci. 2014;14(2):408–413. doi:10.4314/ahs.v14i2.17
   PubMed Web of Science ®Google Scholar
• Araújo-Vilar FS. Diagnosis and treatment of lipodystrophy: a step - by - step approach. J Endocrinol Invest. 2019;42(1):61–73. doi:10.1007/s40618-018-0887-z
   PubMed Web of Science ®Google Scholar
• Della JLB, Luiz MC, Maurici R, Schuelter-Trevisol F. Prevalence and factors associated with lipodystrophy in AIDS patients. Rev Soc Bras Med Trop. 2014;47(1):30–37. doi:10.1590/0037-8682-0240-2013
   PubMed Web of Science ®Google Scholar
• Kinabo GD, Sprengers M, Msuya LJ. Prevalence of Lipodystrophy in HIV-infected Children in Tanzania on Highly Active Antiretroviral Therapy. Pediatr Infect Dis J. 2013;32(1):39–44. doi:10.1097/INF.0b013e3182755a34
   PubMed Web of Science ®Google Scholar
• Tshamala HK, Aketi L, Tshibassu PM, et al. The Lipodystrophy Syndrome in HIV-Infected Children under Antiretroviral Therapy: a First Report from the Central Africa. Int J Pediatr. 2019;2019.
   PubMed Web of Science ®Google Scholar
• Palmeira Dos Santos TM, Barros Da Silva D, Monteiro Franco T, et al. Lipodystrophy and the relationship with cardiovascular risk factors and metabolic syndrome in HIV-infected patients. Nutr Clin y Diet Hosp. 2017;37(2):12–20.
   Google Scholar
• Iwuala SO, Lesi OA, Fasanmade OA, Sabir AA, Olamoyegun MA, Okany CC. Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria. AIDS Res Treat. 2015;1–8.
   Google Scholar
• Kalyanasundaram AP, Jacob SM, Hemalatha R, Sivakumar MR. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India. J Int Assoc Physicians AIDS Care. 2012;11(5):329–334. doi:10.1177/1545109711401750
   Google Scholar
• Aurpibul L, Puthanakit T, Taejaroenkul S, Sirisanthana T, Sirisanthana V. Recovery From Lipodystrophy in HIV – infected Children After Substitution of Stavudine With Zidovudine in a Non-nucleoside Reverse Transcriptase Inhibitor – based. Pediatr Infect Dis J. 2012;31(4):384–388. doi:10.1097/INF.0b013e31823f0e11
   PubMed Web of Science ®Google Scholar
• Tsuda LC, Silva MM, Machado AA, Fernandes APM. Body changes: antiretroviral therapy and lipodystrophy syndrome in people living with HIV/AIDS. Rev Lat Am Enfermagem. 2012;20(5):847–853. doi:10.5999/aps.2020.02285
   PubMed Web of Science ®Google Scholar
• Bwakura-dangarembizi M, Musiime V, Szubert AJ, et al. Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy. Int J Med. 2015;34(2):23–31.
   Google Scholar
• Bouatou Y, Ageron AG, Bernasconi E, et al. Development in HIV-Positive Patients in Switzerland: the LIPOKID Study. Kidney Int Reports. 2018;3(5):1089–1099. doi:10.1016/j.ekir.2018.04.014
   PubMed Web of Science ®Google Scholar
• Beraldo RA, Dos Santos AP, Guimarães MP, et al. Body fat redistribution and changes in lipid and glucose metabolism in people living with HIV/AIDS. Rev Bras Epidemiol. 2017;20(3):526–536. doi:10.1590/1980-5497201700030014
   PubMedGoogle Scholar
• Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131–137. doi:10.1016/j.jhep.2013.02.007
   PubMed Web of Science ®Google Scholar
• Nzuza S, Zondi S, Hurchund R. Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome and Lipodystrophy. Pathophysiology and Current Therapeutic Interventions. 2017;7(4):103–116.
   Google Scholar
• Tsiodras S, Poulia K, Yannakoulia M, et al. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy – induced metabolic syndrome and lipodystrophy. Metabolism. 2009;58(6):854–859. doi:10.1016/j.metabol.2009.02.012
   PubMed Web of Science ®Google Scholar
• Guira O, Tiéno H, Yaméogo B, et al. Characteristics and factors associated with the clinical forms of lipoatrophy during highly active antiretroviral therapy in Ouagadougou, Burkina Faso. J Int Assoc Provid AIDS Care. 2014;13(2):184–187. doi:10.1177/2325957413503369
   PubMedGoogle Scholar
• Méndez ES, Prado AA, José M, Ruiz F. Correlates of perception of HIV-related lipodystrophy: the importance of fears and concerns. Revistamultidiscipliardelsida. 2015;1(4):20–29.
   Google Scholar
• Verolet CM, Delhumeau-Cartier C, Sartori M, et al. Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders. AIDS Res Ther. 2015;12(1):1–10. doi:10.1186/s12981-015-0061-z
   PubMedGoogle Scholar
• Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7(3):137–150. doi:10.1038/nrendo.2010.199
   PubMed Web of Science ®Google Scholar
• Nilmaria Guzman VV. HIV-Associated Lipodystrophy. Treasure Island(FL): Stat Pearls; 2022:1–8.
   Google Scholar
• Da Silva TAL, Barboza RR, De Andrade RD, et al. Relationship between dietary intake and use of protease inhibitors with anthropometric and biochemical parameters of lipodystrophy in people living with HIV. Nutr Hosp. 2014;30(4):935–940. doi:10.3305/nh.2014.30.4.7638
   PubMed Web of Science ®Google Scholar
• Sacre HP, Chalmers R, Tudor-Williams G, Klassen K, Foster C, Walters RMP. Clinic-based anthropometric measurements of lipodystrophy and associations with antiretroviral therapy in HIV-infected adolescents. HIV Med. 2012;13:78.
   Web of Science ®Google Scholar
• Iwuala SO, Lesi OA, Fasanmade OA, Sabir AA, Olamoyegun MA, Okany CC. Prevalence of and risk factors for lipoatrophy in patients with HIV infection in Nigeria. AIDS Res Treat. 2015;2015:1–7. doi:10.1155/2015/402638
   Google Scholar
• Price J, Hoy J, Ridley E, Nyulasi I, Paul E, Woolley I. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health. 2015;12(3):240–248. doi:10.1071/SH14084
   PubMed Web of Science ®Google Scholar
• Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2016;9(1):59–68. doi:10.1586/17512433.2016.1096772
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism. 2019;96:66–82. doi:10.1016/j.metabol.2019.05.001
   PubMed Web of Science ®Google Scholar
• Akini G, Merve Celik BA. Complications of lipodystrophy syndromes. Presse Med. 2021;50(3):1–7.
   Web of Science ®Google Scholar
• Bruder-Nascimento T, Kress TC, Kennard S, De CEJB. HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor-Dependent Increases in NADPH Oxidase 1 (Nox1), C-C Chemokine Receptor Type 5 (CCR5), and Inflammation Thiago. J Am Hear Assoc. 2020;9:1–25.
   Web of Science ®Google Scholar
• Alves MD, Brites C, Sprinz E. HIV -associated lipodystrophy: a review from a Brazilian perspective. Ther Clin Risk Manag. 2014;10(1):559–566.
   PubMedGoogle Scholar
• Koethe JR, Lagathu C, Lake JE, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1). doi:10.1038/s41572-020-0181-1
   Web of Science ®Google Scholar
• Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5):1802–1810. doi:10.1210/jc.2014-4491
   PubMed Web of Science ®Google Scholar